GYRE

GYRE THERAPEUTICS, INC.

Healthcare · Biotechnology

$92.48 sample

+0.33 (+0.36%) 1D

Market cap

$534.9B

Price as of

2026-10-15

Latest filing

8-K · 2026-09-10

Alerts

8

Price$92.48 +7.80% 3M daily closessample

95.7085.23

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 08INSInsider buy: General Counsel
Sep 30INSInsider sell: Director
Sep 23INSInsider buy: EVP, Operations
Sep 15INSInsider buy: EVP, Operations
Sep 10SECDEF 14A filed
Sep 04INSInsider sell: 10% owner
Aug 31INSInsider buy: Chief Executive Officer
Aug 26INSInsider buy: Chief Financial Officer

Sign up to see the real GYRE record →

Company facts

SEC EDGAR registration

Name: GYRE THERAPEUTICS, INC.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: +40sample, -100 to +100
Reporting currency: USD

Who is positioning in GYRE

sample

Insiders: 31 insider transactions over 90 days, net selling, $816.6M
Congress: No member trades over 90 days
Institutions · 13F: 37 funds hold $2.8B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$27.3B +17.0% y/y

Q4 2024Q3 2026

Inventory$16.4B +17.3% y/y

Q4 2024Q3 2026

Accounts receivable$12.1B +10.3% y/y

Q4 2024Q3 2026

Total debt$31.6B +7.5% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $87.0B -6.1% 3M
Sample peer B: $396.6B +12.5% 3M
Sample peer C: $353.1B -5.0% 3M
Sample peer D: $482.9B -8.3% 3M
Sample peer E: $367.3B -2.7% 3M